|Articles|August 16, 2022

Frozen Meat Pizzas Recalled Due to Possible Metal Contaminants

Author(s)Nina Cosdon

Home Run Inn Frozen Foods sausage pizzas have been recalled after consumers reported finding metal in the pizza.

Home Run Inn Frozen Foods is recalling an approximate 13099 pounds of frozen meat pizza product that may be contaminated, the US Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced on Sunday.

The frozen pizzas, produced on June 6, 2022, are suspected to have been contaminated with metal. The recalled products are 33.5 oz cartons with a “best by” date of 12/03/22 and labelled as “Home Run Inn CHICAGO’S PREMIUM PIZZERIA DELUXE SAUSAGE CLASSIC PIZZA.”

Home Run Inn Frozen Foods notified FSIS that customers were complaining of metal remnants found in the sausage pizza. So far, there have not been any reported injuries or illnesses.

The recalled pizzas have the establishment number “EST. 18498-A” within the US Department of Agriculture (USDA) mark of inspection. The pizzas were shipped to an Illinois distributor and then delivered to retailers.

FSIS is advising consumers and retailers to watch out for these products. The recalled pizzas should not be eaten or sold, and should be thrown away or returned to place of purchase.

Any consumers with questions related to the recall can contact Nick Perrino, Home Run Inn Frozen Foods chief operating officer, at 630-783-9696, extension 2151.

FSIS regularly checks consumers and recalling firms are aware of and adhering to recall protocol. Further recall information can be found at www.fsis.usda.gov/recalls.

Customers looking to report a problem with a meat, poultry, or egg product can do so via the Electronic Consumer Complaint Monitoring System: https://foodcomplaint.fsis.usda.gov/eCCF/.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.